TS-FARMEV Study

Phase 1

Recruiting

• Conditions: Solid tumors refractory to oncospecific treatment.

• Registration Number: RPCEC00000112
• Lead Sponsor: Center for Genetic Engineering and Biotechnology (CIGB), in Havana.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-05-16
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1) Histological diagnosis of a solid tumor refractory to treatment oncospecific. 2) That the patient did not receive more than 2 lines of chemotherapy. 3) last cycle of chemotherapy 4 to 8 weeks after treatment ends oncospecific. 4) Age between 18-75 years inclusive. 5) Written consent from the patient.

Exclusion Criteria

1) Pregnancy and lactation 2) decompensated chronic diseases (hypertension, diabetes mellitus, chronic renal failure, heart failure, hyperthyroidism, epilepsy, severe mental depression). 3) moderate or severe systemic infections that interfere with patient evaluation. 4) Patients with previous diagnosis of bleeding disorders and other chronic decompensated hematopatías (hemophilia, leukemia, etc.). 5) Values ??in clinical laboratory evaluations were normal limits prior to the start of treatment: 6) referred immunosuppressive disease, current drug intake immunosuppressive / immunomodulatory properties. 7) Autoimmune diseases (lupus erythematosus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes mellitus, etc.) and previous severe allergic urticaria, dermatitis, bronchitis, bronchial asthma and persistent. 8) diseases that compromise the patient's consciousness or his ability to give informed consent or cooperate in the trial. 9) Have been included in another trial in the last 8 weeks.

Study & Design

• Study Type: Interventional
• Study Design: Not specified